Tune in to the 2022 Targeted Therapies Forum to explore the critical role of nutrition in cancer treatment, discussed by leading oncologists Drs. Desai, Khalil, Preeshagul, Luo, and Terri Conneran. This enlightening discussion sheds light on the importance of dietary considerations in managing the side effects and boosting the effectiveness of cancer treatment protocols. The experts delve into practical strategies, evidence-based nutritional interventions, and the latest research findings on the subject, offering valuable insights for healthcare professionals involved in oncology. This invaluable resource is brought to you with support from our sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech.…
Author: admin
Navigating the world of cancer care requires ample support for patients and their caregivers. In this enlightening video, Dr. Aakash Desai and Terri Conneran share invaluable insights on how to find the essential resources that empower patients and caregivers throughout the cancer treatment journey. Special thanks to our esteemed sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, who make it possible to provide this critical guidance. For more informative videos like this and to join a community of professionals dedicated to improving cancer care, please visit cancerGRACE.org. To engage in conversation with peers and experts in the field, visit…
Opening up to loved ones about a cancer diagnosis is a deeply personal and often challenging experience. In this thought-provoking session, Drs. Preeshagul, Khalil, Luo, and Terri Conneran offer compassionate guidance on how to approach this sensitive conversation. With the generous support from our sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, we’re able to bring you this crucial dialogue. Whether you’re facing this situation yourself or supporting someone close to you, we invite you to explore further resources and engage with others who understand your journey. Visit cancerGRACE.org for more, and to join the conversation, visit https://cancergrace.org/forum.
Understanding when to adjust cancer treatment is paramount in patient care. In this crucial session, Drs. Desai, Khalil, and Luo shed light on the indicators, strategies, and considerations that guide the decision to change treatment during cancer progression. Supported by our committed sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, this video offers essential insights for patients, caregivers, and healthcare professionals. For further guidance, resources, and community support, please visit cancerGRACE.org. To engage with experts and peers on this vital subject, join the conversation at https://cancergrace.org/forum.
The landscape of treating KRAS+ NSCLC (Non-Small Cell Lung Cancer) is evolving, and understanding how to approach patient care after progression on Sotorasib is vital. In this specialized segment of the 2022 Targeted Therapies Forum, Dr. Jia Luo provides an in-depth examination of therapeutic options for patients who have progressed on Sotorasib. This session is brought to you by our esteemed sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, who enable us to offer invaluable insights to the medical community. For further information on this topic and other related fields in oncology, please visit cancerGRACE.org. To engage with experts,…
Handling the stress associated with cancer scans is a vital aspect of care for both patients and healthcare professionals. In this enlightening session of the 2022 Targeted Therapies Forum, Panelists Conneran, Khalil, Luo, Desai, and Preeshagul shed light on innovative and compassionate methods of stress reduction involving scans. This session is proudly supported by our sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, who make such essential discussions possible. For more comprehensive information on this topic and to explore a treasure trove of resources related to cancer treatment, care, and therapies, please visit cancerGRACE.org. Join the conversation, share your…
Drs. Khalil, Luo, Desai, and Preeshagul in this insightful video from the 2022 Targeted Therapies Forum as they discuss effective methods for stress reduction involving scans for newly diagnosed patients. Their expert advice offers support, guidance, and practical strategies to ease the emotional toll of diagnosis. Supported by our sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, this video is a must-watch for patients, caregivers, and healthcare professionals alike. For more resources and to join the conversation, please visit http://cancerGRACE.org/ or follow the discussion at https://cancergrace.org/forum. Don’t miss the opportunity to learn from leading experts in the field, and…
Dr. Maya Khalil dives into the intricacies of RET+ NSCLC treatments in our 2022 Targeted Therapies Forum. Gain insights as she meticulously compares the efficacy and application of Selpercatinib and Pralsetinib, two leading medications in the field. Supported by our esteemed sponsors #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. For a deeper understanding and to be a part of the larger conversation on RET+ NSCLC, make sure to visit http://cancerGRACE.org/. Engage with experts and peers in our forum: https://cancergrace.org/forum.”
In the esteemed 2022 Targeted Therapies Forum, Dr. Jia Luo, renowned Medical Oncologist from Dana-Farber Cancer Institute and respected Instructor in Medicine at Harvard, alongside Dr. Isabel Preeshagul, Thoracic Medical Oncologist from Memorial Sloan Kettering, dives deep into the realm of KRAS Treatments and Clinical Trials. Specifically, Dr. Jia Luo sheds light on the treatment pathways for KRAS+ NSCLC and provides insights on navigating the complex landscape of clinical trials. Grateful for the support from our sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. To explore more on the latest cancer treatments and engage with a vibrant community, do…
In an inspiring session from the 2022 Targeted Therapies Forum, Terri Conneran, lung cancer survivor and the visionary Founder of KRAS Kickers, shares her profound journey battling KRAS+ NSCLC. Delve into Terri’s story as she unravels the motivation behind establishing KRAS Kickers, a beacon of hope and community for countless others navigating similar health challenges. Special thanks to our valued sponsors for making this enlightening session possible: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. To uncover more insightful stories and groundbreaking discoveries in the world of cancer research, please visit http://cancerGRACE.org/. Engage with experts, survivors, and advocates at https://cancergrace.org/forum.
Dive deep into the world of RET+ NSCLC treatment options with Dr. Maya Khalil, an esteemed Hematology-Oncologist from the Kirklin Clinic of UAB Hospital and an Assistant Professor of Medicine at the University of Alabama at Birmingham. As part of the 2022 Targeted Therapies Forum, Dr. Khalil offers her unparalleled expertise in managing RET Mutated NSCLC, shedding light on the most effective treatments for patients diagnosed with RET+ NSCLC. A heartfelt thank you to our distinguished sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their unwavering support. Yearning for more? Unlock a treasure trove of insights and groundbreaking…
Join Dr. Maya Khalil, renowned Hematology-Oncologist from Kirklin Clinic of UAB Hospital and Assistant Professor at the University of Alabama at Birmingham, as she delves into the intricate realm of RET+ NSCLC. In this exclusive segment from the 2022 Targeted Therapies Forum, Dr. Khalil demystifies the processes behind detecting RET mutations and offers insights into the typical profiles of patients who carry these mutations. A big shoutout to our prestigious sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for backing this endeavor. Hungry for more cutting-edge discussions and breakthroughs in the field of oncology? Make sure to explore http://cancerGRACE.org/.…
Delve deep into the world of RET+ NSCLC with Dr. Maya Khalil, a distinguished Hematology-Oncologist from the Kirklin Clinic of UAB Hospital and an Assistant Professor at the University of Alabama at Birmingham. In this revealing segment from the 2022 Targeted Therapies Forum, Dr. Khalil offers an illuminating case study of a patient she treated, shedding light on the intricacies of RET+ NSCLC and the complexities of gene alterations. We extend our gratitude to our esteemed sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their unwavering support. Eager to dive deeper into oncology’s evolving landscape? Make your way…
Unveiling the latest insights on KRAS+ NSCLC, join Dr. Jia Luo, an esteemed Medical Oncologist at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard, in this riveting session from the 2022 Targeted Therapies Forum. Dr. Luo delves deep into the nuances of managing KRAS Mutated NSCLC, exploring state-of-the-art treatment strategies to benefit patients diagnosed with KRAS+ NSCLC. A special thank you to our generous sponsors for their support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Stay at the forefront of oncological advancements. Dive deeper into our resources at http://cancerGRACE.org/. Engage with pioneers in the field and be…
Decoding the complexities of biopsies for KRAS+ NSCLC, join Dr. Jia Luo, a prominent Medical Oncologist at Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard, in this informative session from the 2022 Targeted Therapies Forum. With an in-depth look into KRAS Mutated NSCLC management, Dr. Luo specifically shines a light on the various biopsy types crucial for KRAS diagnosis. Heartfelt gratitude to our esteemed sponsors for their unwavering support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. For a broader spectrum of resources and insights in the realm of oncology, visit http://cancerGRACE.org/. Join our vibrant community and engage…
Demystifying treatment timelines for KRAS+ NSCLC, the 2022 Targeted Therapies Forum presents Dr. Jia Luo, an esteemed Medical Oncologist from Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard. Dive deep into the intricacies of KRAS Mutated NSCLC management as Dr. Luo meticulously outlines the treatment timelines for patients diagnosed with KRAS+ NSCLC in this enlightening English edition. A massive shoutout to our revered sponsors who have been instrumental in bringing this knowledge to you: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Expand your horizons in oncological treatments and breakthroughs by visiting http://cancerGRACE.org/. Engage, inquire, and connect with…
Explore the landscape of KRAS+ NSCLC treatment in the 2022 Targeted Therapies Forum with Dr. Jia Luo, a distinguished Medical Oncologist from Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard. In this enlightening video, Dr. Luo delves into the prevalence of KRAS+ NSCLC and charts the transformative journey of its treatments over the years. Special thanks to our invaluable sponsors for their unwavering support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Stay informed with the latest in oncology research and insights. Visit http://cancerGRACE.org/ and become an active part of our thriving community at https://cancergrace.org/forum.
Dive deep into the world of Next-Generation Sequencing (NGS) tests in our 2022 Targeted Therapies Forum’s breakout session. Esteemed oncologists Dr. Seetharamu and Dagogo-Jack elucidate the contrasts between RNA and DNA testing methodologies for NSCLC. Unravel the intricacies, advantages, and clinical implications of each method, providing clinicians and patients with a clearer perspective on these critical diagnostic tools. We extend our gratitude to our steadfast sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Stay at the forefront of oncological advancements. Visit http://cancerGRACE.org/ and engage in insightful discussions at https://cancergrace.org/forum.
Welcome to the 2022 Targeted Therapies Forum’s breakout session, where renowned oncologist Dr. Dagogo-Jack delves into the nuances of BRAF and NTRK inhibitors and their pivotal role in early-stage NSCLC. Navigate the intricate pathways of these targeted treatments and understand their transformative potential in revolutionizing the landscape of non-small cell lung cancer (NSCLC) care. Heartfelt appreciation to our dedicated sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. To stay updated on cutting-edge advancements in oncology, please visit http://cancerGRACE.org/. Engage, discuss, and share your insights with a community of experts at https://cancergrace.org/forum.
Delving into the intricate landscape of NSCLC management, the 2022 Targeted Therapies Forum presents a dedicated breakout session on ‘First Line Therapy for BRAF+ and NTRK+ NSCLC’. Join Dr. Seetharamu and Dagogo-Jack as they elucidate the strategies, challenges, and groundbreaking advancements surrounding BRAF and NTRK targeted treatments for non-small cell lung cancer. A huge shoutout to our esteemed sponsors for their unwavering support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Stay at the forefront of oncological innovations by visiting http://cancerGRACE.org/. Join our vibrant community of professionals and enthusiasts, and partake in enriching discussions at https://cancergrace.org/forum.
In a specialized breakout session from the 2022 Targeted Therapies Forum, Dr. Nagashree Seetharamu delves deep into the world of NTRK+ NSCLC treatment. Learn the intricacies of two promising medications, Larotrectinib & Entrectinib, that are setting new benchmarks in the realm of non-small cell lung cancer therapies. Special thanks to our committed sponsors for their continual support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. For cutting-edge insights and groundbreaking discoveries in oncology, ensure to visit http://cancerGRACE.org/. Engage with a community of experts and fellow enthusiasts by joining the conversation at https://cancergrace.org/forum.
Dive into the intricacies of NTRK mutations in non-small cell lung cancer with Dr. Nagashree Seetharamu in this enlightening session from the 2022 Targeted Therapies Forum. Uncover why testing for NTRK mutations is pivotal, and explore the various methodologies employed in the process. Our heartfelt gratitude to our esteemed sponsors for championing this cause: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Stay at the forefront of oncology research and breakthroughs. Visit http://cancerGRACE.org/. Engage with experts and a community driven by the same passion. Join the conversation at https://cancergrace.org/forum.
Ever wondered about the nuances of NTRK mutations in oncology? Join Dr. Nagashree Seetharamu in this enlightening session from the 2022 Targeted Therapies Forum as she delves deep into the specifics of NTRK mutations and their role in cancer. A special thanks to our dedicated sponsors for making this knowledge sharing possible: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. For a deeper dive into the latest in cancer research and treatments, visit http://cancerGRACE.org/. Connect with experts and a community dedicated to understanding and battling cancer. Engage with us at https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Ibiayi Dagogo-Jack examines whether BRAF/MEK combination treatment works in all BRAF+ mutations. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Alejandro Calvo and Jeffrey Thompson answer a question regarding hormonal therapy and cancer treatment. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Drs. Calvo and Thompson discuss Crizotinib as adjuvant treatment for ROS1+ disease, and the importance of genetic testing overall. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Drs. Calvo and Thompson discuss when to use targeted therapy in HER2+ disease, and possible upcoming trials. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Alejandro Calvo answers a question regarding developing a second mutation with ROS1. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Jeffrey Thompson examines results from several trials for HER2+ NSCLC treatments. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Jeffrey Thompson looks at HER2+ NSCLC closely, including treatment options. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Jeffrey Thompson discusses the evolving field of NSCLC treatment, and the importance of targeted therapies. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Alejandro Calvo examines the use of chemotherapy and immunotherapy in ROS1+ NSCLC. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Dive into the ever-evolving world of ROS1+ treatment options with Dr. Alejandro Calvo. In this specialized session from the 2022 Targeted Therapies Forum, learn about the potential benefits of Lorlatinib and Repotrectinib for patients grappling with ROS1+ disease. Our gratitude goes out to our esteemed sponsors for their unwavering support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Craving more insights on cutting-edge cancer treatments? Explore http://cancerGRACE.org/. Engage with our passionate community and renowned experts at https://cancergrace.org/forum.
Unravel the complexities of ROS1+ NSCLC treatment with Dr. Alejandro Calvo. In this illuminating segment from the 2022 Targeted Therapies Forum, delve into the details of Crizotinib and Entrectinib — two promising medications championed for ROS1+ NSCLC care. We’d like to express our heartfelt gratitude to our incredible sponsors for their continued support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Eager to delve deeper into the realm of innovative cancer treatments? Discover more at http://cancerGRACE.org/. Engage with our dynamic community and leading experts at https://cancergrace.org/forum.
Dive deep into ROS1+ NSCLC with Dr. Alejandro Calvo. In this captivating segment from the 2022 Targeted Therapies Forum, gain a comprehensive understanding of ROS1 mutations, the diagnostic tests employed, and the cutting-edge treatment options available. Special thanks to our esteemed sponsors for making this knowledge sharing possible: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. To journey further into the world of advanced cancer therapies and join in the discussion with experts and peers, explore more at http://cancerGRACE.org/ and visit our forum at https://cancergrace.org/forum.
Experience the transformation of lung cancer treatment over the years with Dr. Alejandro Calvo. This 2022 Targeted Therapies Forum session provides an insightful examination into how first-line treatments for NSCLC have evolved, adapting to new discoveries and technological advancements. We express our gratitude to our prestigious sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Their support is pivotal in continuing this essential dialogue. To delve deeper into the vast world of cancer research and treatments, and to connect with a community dedicated to understanding and combating this disease, visit http://cancerGRACE.org/ and engage at https://cancergrace.org/forum.
Considering traveling for a clinical trial? Before you pack your bags, get expert insights from Dr. Angel Qin in this 2022 Targeted Therapies Forum. Dr. Qin delves into the many factors that potential participants should weigh when considering travel for a trial, helping patients and families make informed decisions about their treatment journey. Special thanks to our esteemed sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their unwavering support in our mission to inform and connect the cancer community. To delve deeper into the intricate world of cancer treatments, research, and patient experiences, visit http://cancerGRACE.org/. Join our community…
Disease progression in cancer treatments can be complex, especially when it comes to commonly used medications like Lorlatinib or Osimertinib. Dive deep into this crucial topic with Dr. Millie Das and Angel Qin in the 2022 Targeted Therapies Forum. Unravel the intricacies of how these medications work, why there might be progression, and what steps can be taken next. We are deeply thankful to our sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their commitment to fostering patient education and advocacy. To further your knowledge on the evolving landscape of cancer treatments and therapies, head over to http://cancerGRACE.org/.…
Uncommon mutations present unique challenges in cancer treatments, especially when it comes to EGFR mutations. In the 2022 Targeted Therapies Forum, Dr. Angel Qin and Millie Das provide a comprehensive breakdown of the treatment protocols for these mutations and delve into the intricate issues surrounding insurance complications for mutation testing. Our gratitude extends to our supportive sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, for their dedication to the betterment of cancer research and patient care. Stay informed and ahead in the evolving landscape of cancer treatments. Explore more insights at http://cancerGRACE.org/. For an interactive experience, join our community…
As cancer treatment progresses, managing side effects becomes paramount. In this insightful session from the 2022 Targeted Therapies Forum, Drs. Millie Das and Angel Qin share expert recommendations on treating mouth sores, a common yet distressing side effect. Additionally, for those looking to mitigate other side effects, they guide viewers on finding relevant clinical trials that offer promising solutions. A big thank you to our esteemed sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for championing the cause of cancer research and patient well-being. Empower yourself with more knowledge and stay updated with the latest in cancer care. Dive…
Dive deep into the world of EGFR TKIs with Dr. Millie Das and Angel Qin in this enlightening session from the 2022 Targeted Therapies Forum. Explore the efficacy of EGFR TKIs, their potential combinations, and their strategic use post-chemotherapy to optimize treatment outcomes in cancer patients. A heartfelt acknowledgment to our generous sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech for their unwavering support in advancing cancer research and patient care. Equip yourself with the latest advancements in cancer therapy. Explore further at http://cancerGRACE.org/. Join our dedicated community and be part of the conversation at https://cancergrace.org/forum.
Explore the frontier of ALK+ NSCLC treatments in this in-depth session from the 2022 Targeted Therapies Forum, led by the esteemed Dr. Millie Das. As ALK+ NSCLC continues to be a central topic in oncological research, this video sheds light on the most promising emerging therapies and their potential implications for patient care. Special thanks to our dedicated sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, for their continued support in pushing the boundaries of cancer treatment and research. Stay updated with the latest breakthroughs in cancer treatment and research. Dive deeper at http://cancerGRACE.org/. Engage with a community of…
Addressing the challenges of ALK TKIs, this insightful session from the 2022 Targeted Therapies Forum is brought to you by the distinguished Dr. Millie Das. In the vast landscape of cancer treatments, ALK TKIs have shown significant promise, but like all therapies, they come with their considerations. Huge appreciation to our generous sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Their commitment drives progress in the ever-evolving realm of oncology. For a deeper dive into the advancements and discussions in cancer treatment, explore http://cancerGRACE.org/. Engage and share with our expert community at https://cancergrace.org/forum.
Dive into the dynamic world of ALK+ NSCLC treatment with Dr. Millie Das, a prominent figure in oncology, as she unveils the journey and rigorous processes behind the approval of current medications. Hosted by the 2022 Targeted Therapies Forum, this session offers a rich blend of insight and knowledge. Heartfelt thanks to our esteemed sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, whose dedication fuels the advancement in cancer care. Stay updated with the latest in cancer treatments and join our growing community. Discover more at http://cancerGRACE.org/. For engaging discussions and shared experiences, head over to https://cancergrace.org/forum.
Understanding ALK+ NSCLC? Dive into this illuminating session as Dr. Millie Das, a renowned oncologist, breaks down what ‘ALK+’ signifies in the context of lung cancer. This special segment is part of the 2022 Targeted Therapies Forum, connecting you with the latest insights in oncology. Our deepest appreciation to our dedicated sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech. Your support continually pushes the boundaries of cancer research and patient care. Stay abreast of the evolving world of cancer treatments. Learn more and enrich your knowledge at http://cancerGRACE.org/. Engage, ask, and converse with our global community at https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: Dr. Angel Qin discusses the use of Patritumab Deruxtecan for EGFR+ NSCLC. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Angel Qin looks at the Chrysalis-2 Trial, which studied the combination of Amivantamab and Lazertinib for EGFR+ NSCLC Patients with Progression on Osimertinib and platinum-based chemo. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: Dr. Angel Qin discusses next steps if Osimertinib stops working. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: Dr. Angel Qin examines the various TKIs for EGFR+ NSCLC, and their side effects. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Targeted Therapies Forum 2022, Breakout Session: In this video Dr. Angel Qin explains what EGFR+ lung cancer is. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.